Mandate

Vinge advises Vicore Pharma in connection with a directed share issue

December 04, 2018

The board of directors of Vicore Pharma has resolved, subject to the approval by an extraordinary general meeting, on a directed new issue of shares, whereby Vicore Pharma will raise proceeds of approximately SEK 160 million before issue costs. 

The share issue is directed to a number of selected Swedish and international long-term institutional investors and sector specialist funds, on the basis of a book building procedure conducted by DNB Markets, goetzpartners securities and Zonda Partners.

Vicore Pharma is a Swedish rare disease company focused on interstitial lung diseases and related indications. The company’s shares are admitted to trading on Nasdaq First North. 

Vinge’s team has consisted of Jesper Schönbeck, Johan Winnerblad, Nils Fredrik Dehlin, Amanda Knutsson and Emelie Svanberg.

Anti-counterfeiting – the best way to work to counteract trademark infringement and counterfeiting

Counterfeiting and intellectual property law infringement constitute significant problems for both individual trademarks and companies as well as from a broader societal perspective. In this year’s edition of WTR’s “Anti-Counterfeiting: A Global Guide” we present the most important parts of the Swedish legislation, as well as how companies can create successful preventive measures.
June 07, 2021

Full service within IP gives top ranking

Vinge's IP team has been ranked in the top band by the international guide IP Stars in two areas; Trade mark contentious and Trade mark prosecution - law firms.
May 21, 2021

Extensive amendments to the Swedish Protective Security Act - increased obligations and a comprehensive sanctions system

Extensive amendments to the Swedish Protective Security, which include increased obligations for operators of security-sensitive activities and a comprehensive sanctions system, are proposed to enter into force on 1 December 2021. These changes, which were presented in a Government bill of 18 March 2021, generate new and far-reaching obligations for many companies, especially in view of the severe sanctions that may be imposed if the obligations are not complied with.
May 19, 2021